Aspirin and other non-steroidal anti-inflammatory drugs and risk of colorectal cancer: A Danish cohort study
- First Online:
- Cite this article as:
- Friis, S., Poulsen, A.H., Sørensen, H.T. et al. Cancer Causes Control (2009) 20: 731. doi:10.1007/s10552-008-9286-7
- 271 Downloads
The optimal duration and dose of aspirin and non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) in the potential prevention of colorectal cancer (CRC) have not been established. We examined this issue in the Danish Diet, Cancer, and Health Study.
Self-reported NSAID use at entry (January 1995–May 1997) was updated through June 2006, using a nationwide prescription database. CRC incidence was ascertained from nationwide registers. Cox proportional hazards regression was used to compute confounder-adjusted incidence rate ratios (RRs) and 95% confidence intervals (CIs).
From 51,053 cohort subjects, we identified 615 CRC cases during 1995–2006. Daily aspirin use at entry was associated with a decreased risk of CRC (RR, 0.73; 95% CI, 0.49–1.10). A similar risk reduction was seen among subjects with 10 or more prescriptions for aspirin or non-aspirin NSAIDs and five or more years of follow-up. Most aspirin prescriptions were for 75–150 mg aspirin tablets. Among non-aspirin NSAID users, only those with body mass index (BMI) above 25 showed risk reductions [RR, 0.69 (0.47–1.03) for 10 or more prescriptions].
Long-term consistent use of aspirin or non-aspirin NSAIDs appears necessary to achieve a protective effect against CRC. Further studies of the effective dose of aspirin and the potential interaction between NSAID use and BMI are warranted.